|
Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis |
Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. Journal of Clinical Oncology 2012; 30(26): 3167-3173 Indexing Status Subject indexing assigned by NLM MeSH Aged; Antibodies, Monoclonal, Murine-Derived /adverse effects; Antineoplastic Combined Chemotherapy Protocols /adverse effects; Cost-Benefit Analysis; Cyclophosphamide /adverse effects; Decision Support Techniques; Doxorubicin /adverse effects; Early Diagnosis; Hepatitis B /diagnosis /economics; Hepatitis B Surface Antigens /analysis; Hepatitis B virus; Humans; Lymphoma, Large B-Cell, Diffuse /drug therapy /economics /virology; Middle Aged; Prednisone /adverse effects; Treatment Outcome; Vincristine /adverse effects; Virus Activation /drug effects AccessionNumber 22012036943 Date bibliographic record published 04/01/2013 |
|
|
|